# Anakinra for COVID-19 Respiratory Symptoms

> **NCT04364009** · PHASE3 · TERMINATED · sponsor: **University Hospital, Tours** · enrollment: 71 (actual)

## Conditions studied

- COVID-19 Infection
- ANAKINRA Treatment
- Optimized Standard of Care (oSOC)

## Interventions

- **DRUG:** Anakinra plus oSOC
- **DRUG:** oSOC

## Key facts

- **NCT ID:** NCT04364009
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-27
- **Primary completion:** 2020-10-20
- **Final completion:** 2020-11-03
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Efficiency and safety reasons
- **Last updated:** 2021-01-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364009, "Anakinra for COVID-19 Respiratory Symptoms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04364009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*